Isofol Sets TO1 Warrant Price and Exercise Window, Targets SEK 19 Million Raise

Isofol Medical AB ( (SE:ISOFOL) ) has issued an update.

Isofol Medical has set the subscription price for its series TO1 warrants at SEK 0.48 per share, equal to 70 percent of the recent volume-weighted average share price, with an exercise window running from 16 to 30 March 2026. Full exercise of the 39,863,928 warrants could raise about SEK 19.1 million, increasing the share count by roughly 12.4 percent and diluting existing shareholders accordingly.

To bolster the warrant exercise, Isofol has secured a top guarantee commitment from partner Solasia Pharma covering about 5.3 percent of potential proceeds, alongside non-binding letters of intent from major shareholders, management and the board representing a further 36 percent. Together these commitments, provided without compensation, cover around 42 percent of the possible capital raise, signalling internal and partner support but leaving execution risk as warrants will expire worthless if not exercised or sold by the stated deadlines.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.64 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

More about Isofol Medical AB

Isofol Medical AB is a Swedish biotechnology company based in Gothenburg and listed on Nasdaq Stockholm. The company focuses on developing oncology treatments and collaborates with partners such as Japan’s Solasia Pharma K.K. for development and commercialisation in selected markets.

Average Trading Volume: 1,478,815

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK187.6M

Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.